Relatlimab | sciencenewsnet.in

Breaking News

Columbia Nursing Study Gauges Effectiveness of COVID-19 Burden Mitigation Policies

New gene signature could transform immunotherapy for gastrointestinal cancers

A Rare and Little-Known Group of Monkeys Could Help Save Africa’s Tropical Forests

Advancing genomic medicine: National Cancer Center Japan’s role in personalized cancer treatment

Experts and Research on ARFID

New breast cancer screening recommendations aim to address health inequities, especially among Black women

Unlocking the immune system: cGAS-STING pathway offers new hope for cancer breakthroughs

Rubin Observatory Achieves Another Major Milestone: Reflective Coating of the 8.4-meter Primary/Tertiary Mirror

Biodegradable ‘living plastic’ houses bacterial spores that help it break down

Machine Listening: Making Speech Recognition Systems More Inclusive

30 Apr, 2024

Clinical Trial Results Published in Nature Medicine Show Immunotherapy’s Potential in Resectable Esophageal and Gastroesophageal Junction Cancers and the Benefits of Monitoring Circulating Tumor DNA (ctDNA) to Measure Disease Response

March 20, 2024 sarah JonasResearch Results

The results of a study published today in Nature Medicine show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy. The study results also show the potential for monitoring circulating tumor DNA as a predictor for future intervention.